March 23, 2023
Journal of Clinical Psychiatry Publishes Data from Alkermes' ENLIGHTEN-Early Study of LYBALVI® (olanzapine and samidorphan) in Young Adults Early in...
February 16, 2023
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2022 and Provides Financial Expectations for 2023
Hear from Markus Haeberlein, Ph.D. where he discusses our commitment to researching potential treatment options for people living with sleep disorders.
This Women’s History Month, we celebrate the accomplishments of the many women making a difference at Alkermes. Meet the co-leads of Mosaic, our ERG dedicated to multicultural diversity.
Hear from Dr. Craig Hopkinson in this PharmaVoice article where he discusses our commitment to developing novel potential therapies for people living with difficult-to-treat cancers.
Alkermes is focused on developing innovative medicines that seek to address unmet needs of people living with serious mental illness, addiction and cancer. As a fully-integrated, global biopharmaceutical company, with U.S. locations in Massachusetts and Ohio, and locations in Dublin and Athlone, Ireland, we apply our scientific expertise and proprietary technologies to develop products designed to make a meaningful difference in the way people manage their diseases. Beyond our scientific pursuits, we also work to help support and enhance the systems through which these complex diseases are treated. We are committed to patient engagement, disease education and supporting policies that enable access to approved treatment options.